Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Gaining a Better Understanding of Kidney Diseases

No. 43 | 26/08/2008 | by (Koh)

By introducing a genetic switch in mice it is possible to increase or decrease the production of specific protein molecules in their kidneys. Thus, researchers can study the influence of specific proteins on disease development. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg University Hospitals and other research institutes have published this model of investigating severe kidney diseases in the latest issue of Nature medicine.

Cystic kidney disease, renal fibrosis, or renal cell carcinoma: Many diseases of the excretory organs are characterized by overproduction or – on the contrary – absence of characteristic proteins in the renal cells. An international research team under the leadership of scientists from DKFZ and Heidelberg University Hospitals has now developed an animal model to better investigate these conditions.

The researchers introduced a genetic switch into the genome of mice. This switch allows to selectively turn on and off the production of disease-typical proteins in renal tissue. It is activated simply by adding the antibiotic tetracycline to the animal food.

To find out whether it is possible to study the development of kidney diseases in the genetically modified (transgenic) animals, the investigators stimulated the production of c-Myc in the renal tissue of the mice. Numerous tumors have been reported to be associated with elevated levels of this transcription factor. Shortly after activation of the c-Myc gene the animals started developing cysts that led to organ failure. Pathologists also discovered renal cell carcinomas in some of the mice. As a reaction to the overexpression of another signaling molecule, the mice developed renal fibrosis.

Earlier attempts to study disease development using transgenic animals have often failed because the proteins to be studied are overproduced in the murine embryos already. As a result, the animals often develop severe malformations that make meaningful conclusions impossible. “A particular advantage of our model is that we can switch on and off disease-typical renal proteins at any given time,” explained Associate Professor (PD) Dr. Robert Kösters of the Institute of Human Genetics of the University of Heidelberg and Professor Dr. Hermann-Josef Gröne of the German Cancer Research Center. “Thus, we are able to simulate the natural course of disease development and also of healing processes.”

Milena Traykova-Brauch, Kai Schönig, Oliver Greiner, Tewfik Miloud, Anna Jauch, Manja Bode, Dean W Felsher, Adam B Glick, David J Kwiatkowski, Hermann Bujard, Jürgen Horst, Magnus von Knebel Doeberitz, Felix K Niggli, Wilhelm Kriz, Hermann-Josef Gröne and Robert Koesters: An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nature medicine, 24 August 2008

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS